Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bowman, G. L.
Right arrow Articles by Quinn, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bowman, G. L.
Right arrow Articles by Quinn, J. F.
Related Collections
Right arrow Volumetric MRI
Right arrow Cerebrospinal Fluid
Right arrow Alzheimer's disease
NEUROLOGY 2007;68:1809-1814
© 2007 American Academy of Neurology

Blood–brain barrier impairment in Alzheimer disease

Stability and functional significance

G. L. Bowman, ND, J. A. Kaye, MD, M. Moore, BS, D. Waichunas, BA, N. E. Carlson, PhD and J. F. Quinn, MD

From the Department of Neurology (G.L.B., J.A.K., J.F.Q.), Layton Aging and Alzheimer's Disease Center (J.A.K., M.M., D.W., N.E.C., J.F.Q.), Oregon Center for Complementary and Alternative Medicine in Neurological Disorders (G.L.B.), and Division of Biostatistics (N.E.C.), Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland.

Address correspondence and reprint requests to Dr Bowman, 3181 Southwest Sam Jackson Park Rd., CR-131, Portland, OR 97239 bowmang{at}ohsu.edu

Objective: To determine the stability and functional significance of blood–brain barrier (BBB) integrity in patients with mild to moderate Alzheimer disease (AD).

Methods: Thirty-six patients (mean age 71 ± 7 years) with mild to moderate AD (Mini-Mental State Examination [MMSE] 19 ± 5) participated in a biomarker study involving clinical assessments, brain imaging, and CSF and plasma collection over 1 year. BBB integrity was assessed with the CSF–albumin index (CSF-AI).

Results: BBB disruption was present in an important subgroup of patients (n = 8/36, 22%) at all time points measured. CSF-AI was highly reproducible over 1 year with an intraclass correlation of 0.96. Age, sex, and APOE status did not correlate with CSF-AI. Vascular factors (blood pressure, Hachinski ischemia score, MR-derived white matter hyperintensity, body mass index) were not strongly associated with CSF-AI levels (p = 0.066). CSF/plasma IgG ratio correlated with CSF-AI in a manner indicating that peripheral IgG has greater access to the CNS in patients with an impaired BBB. Further evidence for the physiologic significance of the CSF-AI was noted in the form of correlations with rates of disease progression, including annual change on MMSE (r2 = 0.11, p = 0.023), annual Clinical Dementia Rating sum-of-boxes change (r2 = 0.29, p = 0.001), and annual ventricular volume change (r2 = 0.17, p = 0.007).

Conclusions: Blood–brain barrier (BBB) impairment is a stable characteristic over 1 year and present in an important subgroup of patients with Alzheimer disease. Age, gender, APOE status, vascular risk factors, and baseline Mini-Mental State Examination score did not explain the variability in BBB integrity. A role for BBB impairment as a modifier of disease progression is suggested by correlations between CSF–albumin index and measures of disease progression over 1 year.

Received November 21, 2006. Accepted in final form January 22, 2007.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.